HEART FAILURE FROM DIABETES DRUGS, ONGLYZA & KOMBIGLYZE XR- Federal Cases Centralized in the Eastern District of Kentucky

Diabetes Drug Lawsuits

On February 2, 2018, the Judicial Panel on Multidistrict Litigation (JPML) centralized federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR) in multidistrict litigation (“MDL”) in the U.S. District Court, Eastern District of Kentucky before the Honorable Karen K. Caldwell. Saxagliptin is…

Read More

SGLT2 Diabetes Drugs Associated with Doubled Risk of Dangerous Levels of Acid in Blood

Medical Drug Safety

A cohort study of 140,352 diabetics showed that sodium-glucose cotransporter 2 (SGLT2 inhibitors) diabetes drugs were associated with approximately twice the risk of diabetic ketoacidosis as were dipeptidyl peptidase-4 (DPP4 inhibitors) diabetes drugs according to a recent letter to the New England Journal of Medicine. SGLT2 inhibitors are a class of prescription medicines that are…

Read More